Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Redx Pharma
Redx Pharma
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Redx signs licensing agreement with AstraZeneca for porcupine inhibitor
AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis
Finance
Redx Pharma appoints Sarah Gordon as non-executive Director
Gordon has been appointed due to deep experience of the biotechnology industry and capital markets
Research & Development
Redx Pharma announces new drug development candidate for fibrosis
First-in-human studies earmarked for 2020
Research & Development
Quay Pharma to supply promising cancer drug for trial
Quay Pharma has reached an agreement with Redx Pharma to manufacture Redx’s breakthrough cancer treatment drug
Research & Development
Redx Pharma set for new HQ at Alderley Park, Cheshire
Will bring together its three subsidiaries Redx Oncology, Redx Anti-Infectives and Redx Immunology onto one site
Research & Development
Redx Pharma launches £24m immunology R&D centre
Receives £4.2m of funding from the UK Government's Regional Growth Fund to be matched with proceeds from AIM listing
Research & Development
Redx Pharma and Pierre Fabre collaborate in skin cancer drug field
Will together develop a small molecule programme for an undisclosed cancer target
Subscribe now